Keystone Financial Planning Inc. trimmed its holdings in GlaxoSmithKline plc (NYSE:GSK) by 3.1% in the 4th quarter, HoldingsChannel.com reports. The firm owned 129,102 shares of the pharmaceutical company’s stock after selling 4,114 shares during the quarter. GlaxoSmithKline makes up approximately 2.4% of Keystone Financial Planning Inc.’s portfolio, making the stock its 20th largest holding. Keystone Financial Planning Inc.’s holdings in GlaxoSmithKline were worth $4,579,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also bought and sold shares of GSK. Gotham Asset Management LLC boosted its stake in GlaxoSmithKline by 4.3% in the 2nd quarter. Gotham Asset Management LLC now owns 26,495 shares of the pharmaceutical company’s stock worth $1,142,000 after purchasing an additional 1,103 shares during the period. The Manufacturers Life Insurance Company boosted its stake in GlaxoSmithKline by 18.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,960 shares of the pharmaceutical company’s stock worth $818,000 after purchasing an additional 2,968 shares during the period. Americafirst Capital Management LLC bought a new position in GlaxoSmithKline in the 2nd quarter worth approximately $299,000. Nomura Holdings Inc. bought a new position in GlaxoSmithKline in the 2nd quarter worth approximately $265,000. Finally, Verition Fund Management LLC bought a new position in GlaxoSmithKline in the 2nd quarter worth approximately $1,300,000. Institutional investors and hedge funds own 9.66% of the company’s stock.

Several research firms have weighed in on GSK. Zacks Investment Research upgraded GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a research note on Wednesday, October 18th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research report on Wednesday, October 18th. Bank of America downgraded GlaxoSmithKline from a “buy” rating to a “neutral” rating in a research report on Thursday, October 26th. ValuEngine downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, UBS Group reiterated a “buy” rating on shares of GlaxoSmithKline in a research report on Monday, January 15th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $38.57.

GlaxoSmithKline plc (GSK) opened at $36.49 on Friday. The company has a current ratio of 0.60, a quick ratio of 0.44 and a debt-to-equity ratio of 4.09. The company has a market capitalization of $89,664.49, a P/E ratio of 46.19, a PEG ratio of 2.32 and a beta of 0.98. GlaxoSmithKline plc has a 52-week low of $34.52 and a 52-week high of $44.53.

GlaxoSmithKline (NYSE:GSK) last posted its earnings results on Wednesday, February 7th. The pharmaceutical company reported $0.72 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.03. The firm had revenue of $10.14 billion during the quarter, compared to the consensus estimate of $9.89 billion. GlaxoSmithKline had a return on equity of 130.63% and a net margin of 4.97%. sell-side analysts predict that GlaxoSmithKline plc will post 2.8 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 12th. Investors of record on Friday, February 23rd will be given a $0.633 dividend. The ex-dividend date of this dividend is Thursday, February 22nd. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.50. This represents a $2.53 dividend on an annualized basis and a yield of 6.94%. GlaxoSmithKline’s dividend payout ratio (DPR) is currently 258.23%.

COPYRIGHT VIOLATION NOTICE: “GlaxoSmithKline plc (GSK) Holdings Trimmed by Keystone Financial Planning Inc.” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://theolympiareport.com/2018/02/10/glaxosmithkline-plc-gsk-holdings-trimmed-by-keystone-financial-planning-inc.html.

GlaxoSmithKline Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.